Strs Ohio Has $223.45 Million Stake in Eli Lilly and Company $LLY

Strs Ohio cut its stake in Eli Lilly and Company (NYSE:LLY) by 13.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 292,858 shares of the company’s stock after selling 46,646 shares during the quarter. Eli Lilly and Company accounts for about 0.8% of Strs Ohio’s portfolio, making the stock its 15th biggest position. Strs Ohio’s holdings in Eli Lilly and Company were worth $223,451,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Sumitomo Mitsui Financial Group Inc. purchased a new position in Eli Lilly and Company during the 2nd quarter worth $27,000. Evolution Wealth Management Inc. bought a new stake in Eli Lilly and Company during the second quarter worth $29,000. Steph & Co. grew its stake in Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after purchasing an additional 29 shares during the period. Financial Gravity Companies Inc. purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $31,000. Finally, Bare Financial Services Inc raised its stake in shares of Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 29 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Launched a Phase 3b dosing study for retatrutide in obesity, advancing a leading obesity candidate toward optimized dosing and broader label/market potential. Eli Lilly Advances Retatrutide With New Phase 3b Obesity Dosing Study
• Positive Sentiment: Retatrutide trial data suggest potential knee osteoarthritis symptom benefit tied to weight loss — could expand clinical and commercial appeal beyond pure weight metrics. Eli Lilly’s Retatrutide Trial Links Obesity Treatment With Knee Osteoarthritis Relief Potential
• Positive Sentiment: SURMOUNT‑REAL UK (phase 4) will provide real‑world tirzepatide data in obesity — useful for uptake, payer conversations and long‑term market sizing. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: FDA granted Breakthrough Therapy designation to sofetabart (mipitecan) for certain platinum‑resistant ovarian cancer patients — accelerates development path and raises long-term oncology upside. FDA Grants Breakthrough Therapy Tag to LLY’s Ovarian Cancer Candidate
• Positive Sentiment: Initiated a Phase 2 oral pain program for diabetic nerve pain — diversification of pipeline into high‑unmet‑need pain indications could add medium‑term value. Eli Lilly Expands Its Pain Pipeline With New Phase 2 Trial in Diabetic Nerve Pain
• Neutral Sentiment: Announced a Phase 1 PET tracer imaging study to broaden oncology imaging capabilities — early stage, strategic but long‑timeline impact. Eli Lilly Expands Oncology Imaging Footprint With New Phase 1 PET Tracer Study
• Neutral Sentiment: Confirmed Q4 2025 earnings date (Feb 4) — sets the calendar for next major catalyst and likely some pre‑earnings positioning. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Market commentary pieces (buy/preview, breakout) and an explainer on why LLY is up today summarize investor enthusiasm and momentum ahead of results; useful but opinion‑driven. Why Eli Lilly (LLY) stock is up today
• Negative Sentiment: Coverage notes Novo Nordisk’s new CEO is expected to intensify competition in obesity treatments — a reminder of pricing, market‑share and reimbursement risks. Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026

Eli Lilly and Company Trading Up 0.8%

Shares of LLY stock opened at $1,087.63 on Friday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company’s fifty day simple moving average is $1,056.39 and its two-hundred day simple moving average is $878.04. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The stock has a market capitalization of $1.03 trillion, a price-to-earnings ratio of 53.21, a PEG ratio of 0.81 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Analysts Set New Price Targets

LLY has been the subject of several research reports. CICC Research increased their price target on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Friday, December 19th. Guggenheim lowered their price target on shares of Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating on the stock in a report on Tuesday. Scotiabank started coverage on Eli Lilly and Company in a report on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 price objective for the company. Finally, UBS Group started coverage on Eli Lilly and Company in a research report on Tuesday, January 6th. They issued a “buy” rating and a $1,250.00 target price for the company. Four equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $1,174.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.